Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| General Surgery | 6 | 2022 | 210 | 1.080 |
Why?
|
| Wounds and Injuries | 3 | 2021 | 247 | 1.010 |
Why?
|
| Spatial Analysis | 1 | 2021 | 12 | 0.710 |
Why?
|
| Heart Transplantation | 1 | 2022 | 169 | 0.700 |
Why?
|
| Clinical Clerkship | 2 | 2022 | 91 | 0.690 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 144 | 0.670 |
Why?
|
| Intensive Care Units | 3 | 2017 | 406 | 0.610 |
Why?
|
| Conservative Treatment | 1 | 2018 | 17 | 0.590 |
Why?
|
| Appendectomy | 1 | 2018 | 54 | 0.580 |
Why?
|
| Autism Spectrum Disorder | 1 | 2021 | 180 | 0.570 |
Why?
|
| Schools, Medical | 3 | 2020 | 145 | 0.560 |
Why?
|
| Appendicitis | 1 | 2018 | 81 | 0.560 |
Why?
|
| Pneumonia, Viral | 1 | 2021 | 225 | 0.550 |
Why?
|
| Patient Discharge | 1 | 2021 | 511 | 0.550 |
Why?
|
| Professional-Family Relations | 1 | 2017 | 88 | 0.500 |
Why?
|
| Clinical Competence | 2 | 2017 | 725 | 0.460 |
Why?
|
| Family | 1 | 2017 | 238 | 0.460 |
Why?
|
| Curriculum | 3 | 2022 | 591 | 0.450 |
Why?
|
| Heart Failure | 1 | 2022 | 913 | 0.440 |
Why?
|
| Patient Care Team | 1 | 2017 | 337 | 0.430 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 254 | 0.430 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2015 | 46 | 0.410 |
Why?
|
| Internship and Residency | 4 | 2022 | 801 | 0.380 |
Why?
|
| Injury Severity Score | 2 | 2021 | 109 | 0.350 |
Why?
|
| Blood Component Transfusion | 1 | 2011 | 11 | 0.350 |
Why?
|
| Shock, Hemorrhagic | 1 | 2011 | 20 | 0.350 |
Why?
|
| Resuscitation | 1 | 2011 | 67 | 0.330 |
Why?
|
| Length of Stay | 4 | 2021 | 811 | 0.330 |
Why?
|
| Students, Medical | 4 | 2022 | 256 | 0.320 |
Why?
|
| Humans | 31 | 2022 | 63283 | 0.310 |
Why?
|
| Prospective Studies | 5 | 2022 | 3280 | 0.290 |
Why?
|
| Male | 19 | 2021 | 29799 | 0.260 |
Why?
|
| Burnout, Professional | 2 | 2019 | 135 | 0.250 |
Why?
|
| Attitude to Health | 2 | 2019 | 289 | 0.240 |
Why?
|
| Career Choice | 2 | 2017 | 131 | 0.240 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2017 | 157 | 0.240 |
Why?
|
| Female | 18 | 2021 | 32776 | 0.240 |
Why?
|
| Parvovirus B19, Human | 1 | 2004 | 5 | 0.230 |
Why?
|
| Parvoviridae Infections | 1 | 2004 | 23 | 0.230 |
Why?
|
| Diseases in Twins | 1 | 2004 | 55 | 0.220 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2004 | 76 | 0.220 |
Why?
|
| Young Adult | 6 | 2021 | 4683 | 0.220 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2004 | 65 | 0.220 |
Why?
|
| Pennsylvania | 2 | 2021 | 64 | 0.210 |
Why?
|
| Retrospective Studies | 5 | 2021 | 6627 | 0.200 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2022 | 12 | 0.200 |
Why?
|
| Patient Handoff | 1 | 2022 | 35 | 0.190 |
Why?
|
| Critical Illness | 2 | 2016 | 322 | 0.180 |
Why?
|
| Odds Ratio | 2 | 2021 | 768 | 0.180 |
Why?
|
| Geographic Mapping | 1 | 2021 | 8 | 0.180 |
Why?
|
| Geographic Information Systems | 1 | 2021 | 23 | 0.180 |
Why?
|
| Mesenteric Veins | 1 | 2020 | 11 | 0.170 |
Why?
|
| Heart Ventricles | 1 | 2022 | 264 | 0.170 |
Why?
|
| Trauma Centers | 1 | 2021 | 123 | 0.170 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1121 | 0.160 |
Why?
|
| Clostridium Infections | 1 | 2020 | 49 | 0.160 |
Why?
|
| Social Media | 1 | 2022 | 128 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 115 | 0.160 |
Why?
|
| Pandemics | 2 | 2022 | 674 | 0.160 |
Why?
|
| Occupational Stress | 1 | 2019 | 20 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 2020 | 149 | 0.150 |
Why?
|
| Adult | 10 | 2021 | 16771 | 0.150 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 777 | 0.150 |
Why?
|
| Self Efficacy | 1 | 2019 | 201 | 0.140 |
Why?
|
| Test Taking Skills | 1 | 2017 | 2 | 0.140 |
Why?
|
| Pain Management | 1 | 2019 | 161 | 0.140 |
Why?
|
| Health Resources | 1 | 2017 | 95 | 0.130 |
Why?
|
| Licensure | 1 | 2016 | 13 | 0.130 |
Why?
|
| Prevalence | 1 | 2021 | 1377 | 0.130 |
Why?
|
| Workflow | 1 | 2017 | 69 | 0.130 |
Why?
|
| Acute Disease | 1 | 2018 | 672 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2017 | 82 | 0.130 |
Why?
|
| Communication | 2 | 2022 | 573 | 0.130 |
Why?
|
| Hospitals, University | 1 | 2016 | 54 | 0.130 |
Why?
|
| Social Support | 1 | 2019 | 371 | 0.130 |
Why?
|
| Community-Institutional Relations | 1 | 2016 | 38 | 0.130 |
Why?
|
| Middle Aged | 9 | 2021 | 17535 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2022 | 5647 | 0.130 |
Why?
|
| Wounds, Gunshot | 1 | 2016 | 56 | 0.120 |
Why?
|
| B-Lymphocytes | 2 | 2015 | 574 | 0.120 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2015 | 3 | 0.120 |
Why?
|
| Benzoates | 1 | 2015 | 8 | 0.120 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2015 | 20 | 0.120 |
Why?
|
| Th17 Cells | 1 | 2015 | 61 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 318 | 0.120 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 5443 | 0.120 |
Why?
|
| Enoxaparin | 1 | 2015 | 18 | 0.120 |
Why?
|
| Educational Measurement | 1 | 2017 | 217 | 0.120 |
Why?
|
| Firearms | 1 | 2016 | 69 | 0.120 |
Why?
|
| Depsipeptides | 1 | 2015 | 5 | 0.120 |
Why?
|
| Interleukin-15 | 1 | 2015 | 25 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 9 | 0.120 |
Why?
|
| Brain Edema | 1 | 2015 | 31 | 0.120 |
Why?
|
| Tissue Adhesions | 1 | 2015 | 20 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 36 | 0.120 |
Why?
|
| Interleukin-17 | 1 | 2015 | 94 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 36 | 0.120 |
Why?
|
| Health Education | 1 | 2016 | 189 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 41 | 0.110 |
Why?
|
| Survivors | 1 | 2016 | 170 | 0.110 |
Why?
|
| Leukocytes | 1 | 2015 | 104 | 0.110 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 53 | 0.110 |
Why?
|
| Intestine, Small | 1 | 2015 | 79 | 0.110 |
Why?
|
| Adolescent | 3 | 2021 | 6238 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 784 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 447 | 0.110 |
Why?
|
| Incidence | 1 | 2018 | 1375 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2016 | 488 | 0.110 |
Why?
|
| Frail Elderly | 1 | 2015 | 109 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 175 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2015 | 245 | 0.110 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2015 | 211 | 0.110 |
Why?
|
| NF-kappa B | 1 | 2015 | 469 | 0.100 |
Why?
|
| Surgeons | 1 | 2016 | 187 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 421 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 192 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 590 | 0.100 |
Why?
|
| Critical Care | 1 | 2016 | 397 | 0.100 |
Why?
|
| Depression | 1 | 2019 | 891 | 0.100 |
Why?
|
| Torque teno virus | 1 | 2011 | 1 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 755 | 0.090 |
Why?
|
| Polycythemia Vera | 1 | 2011 | 7 | 0.090 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2011 | 28 | 0.090 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 397 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2015 | 495 | 0.090 |
Why?
|
| Cellular Senescence | 1 | 2011 | 110 | 0.090 |
Why?
|
| Genome, Viral | 1 | 2011 | 136 | 0.090 |
Why?
|
| Cell Division | 1 | 2011 | 449 | 0.080 |
Why?
|
| United States | 3 | 2020 | 7828 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 412 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 663 | 0.080 |
Why?
|
| Aged | 8 | 2020 | 14384 | 0.080 |
Why?
|
| Quality of Life | 1 | 2015 | 1223 | 0.070 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 350 | 0.070 |
Why?
|
| Hospitalization | 1 | 2014 | 1355 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2015 | 985 | 0.060 |
Why?
|
| Remission Induction | 2 | 2015 | 148 | 0.060 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2004 | 6 | 0.060 |
Why?
|
| Fetal Death | 1 | 2004 | 14 | 0.060 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2004 | 43 | 0.060 |
Why?
|
| Infant, Premature | 1 | 2004 | 184 | 0.050 |
Why?
|
| Feedback | 1 | 2022 | 88 | 0.050 |
Why?
|
| Patients | 1 | 2022 | 113 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2015 | 2152 | 0.040 |
Why?
|
| Prognosis | 2 | 2015 | 1750 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2004 | 1355 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2015 | 1348 | 0.040 |
Why?
|
| Acute Pain | 1 | 2019 | 21 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 102 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 850 | 0.040 |
Why?
|
| Pregnancy | 1 | 2004 | 2330 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2019 | 151 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 3757 | 0.030 |
Why?
|
| Traumatology | 1 | 2016 | 15 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 1649 | 0.030 |
Why?
|
| Philadelphia | 1 | 2016 | 21 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2020 | 430 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2016 | 97 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 47 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 180 | 0.030 |
Why?
|
| Trust | 1 | 2016 | 73 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2015 | 3 | 0.030 |
Why?
|
| Arsenicals | 1 | 2015 | 8 | 0.030 |
Why?
|
| Febrile Neutropenia | 1 | 2015 | 6 | 0.030 |
Why?
|
| Oxides | 1 | 2015 | 35 | 0.030 |
Why?
|
| Child | 2 | 2016 | 4522 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2015 | 28 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 42 | 0.030 |
Why?
|
| Mesenteric Ischemia | 1 | 2015 | 6 | 0.030 |
Why?
|
| Naphthalimides | 1 | 2015 | 2 | 0.030 |
Why?
|
| Daunorubicin | 1 | 2015 | 7 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 52 | 0.030 |
Why?
|
| Tretinoin | 1 | 2015 | 50 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 46 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2015 | 3033 | 0.030 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2015 | 60 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2015 | 75 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 189 | 0.030 |
Why?
|
| Cytarabine | 1 | 2015 | 35 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 67 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2015 | 22 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 242 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2015 | 58 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 50 | 0.030 |
Why?
|
| Epigenomics | 1 | 2015 | 62 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 174 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2015 | 204 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 174 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 372 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 298 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 422 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 376 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2675 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 163 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 197 | 0.030 |
Why?
|
| Brain Injuries | 1 | 2015 | 139 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 643 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 280 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 937 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| Palliative Care | 1 | 2015 | 228 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 349 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 357 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 388 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 668 | 0.020 |
Why?
|
| CD5 Antigens | 1 | 2011 | 18 | 0.020 |
Why?
|
| DNA Virus Infections | 1 | 2011 | 8 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 506 | 0.020 |
Why?
|
| Blood Donors | 1 | 2011 | 23 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2011 | 68 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 24 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2011 | 36 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 2011 | 36 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2011 | 51 | 0.020 |
Why?
|
| Clone Cells | 1 | 2011 | 114 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2011 | 195 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 207 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2011 | 232 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1073 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 760 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2014 | 874 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2460 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 771 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 834 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1177 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 10827 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 20634 | 0.010 |
Why?
|